Pain Management News

ORLANDO, Fla. — Patients with MS who developed paramagnetic rim lesions declined more rapidly, but implementing disease-modifying therapies earlier could reduce the burden of disease progression, data show.

The FDA has granted clearance to a Colorado-based medical technology company’s transcutaneous electrical nerve stimulation device for those suffering from chronic pain, according to a press release.

The FDA has accepted the resubmission of a new drug application for a novel, oral therapeutic intended to treat individuals with acute migraine, according to the manufacturer.

A novel digital therapeutic for migraine prevention met its primary endpoint of reducing the number of monthly migraine days, according to results from a phase 3 clinical trial.

In patients with difficult-to-treat migraine, IV infusion of a novel monoclonal antibody provided superior migraine frequency relief compared with placebo in as early as 4 weeks, data show.

Prodromal treatment with 100 mg ubrogepant was associated with greater functionality, fewer activity limitations and a high degree of satisfaction at 24 hours in patients with migraine, according to research published in Neurology.

According to results of a six-nation global survey, individuals with migraine experienced a high level of symptom burden and severity, negatively affecting their quality of life including mood.

Deep brain stimulation (DBS) therapy has been a safe and effective treatment option for Parkinson’s disease for more than 30 years, but another surgical option for the therapy has emerged.

A Maryland-based neurotechnology company has secured a U.S. patent for its novel prosthetic translucent, cranial implant intended for use during neurosurgical procedures.